In addition, a recent phase II clinical trial observed that combinational use of metformin with standard epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy significantly improved both progression-free survival and overall survival in patients with advanced lung adenocarcinoma (NCT03071705; Table 2) [257]. The gene discussed is EGFR; the disease is lung adenocarcinoma.